JB Chemicals' CDMO business is expected to sustain robust growth through geographical expansion and product diversification.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
JB Chemicals and Pharmaceuticals Ltd. is poised for double-digit growth, driven by strong domestic and contract development manufacturing organisation performance, along with high return ratios. The CDMO business is expected to sustain robust growth through geographical expansion and product diversification.
We maintain a Buy rating with a target price of Rs 2,143, valuing it at 22 times Dec'26E enterprise value/Ebitda (a 10% premium to the five-year average).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
